Mianserin and doxepin in the treatment of outpatient depression with anxiety.
1 A double-blind group comparative trial was performed comparing mianserin (Bolvidon-Organon) and doxepin (Sinequan-Pfizer) in the treatment of depression with anxiety. 2 Sixty outpatients from two centres were divided into 'high' and 'low' severity groups, based on initial HRS scores, and treated for four weeks. 3 Standard rating scales for depression and anxiety demonstrated a substantial improvement with both drugs. However, no consistent difference in efficacy was found although the 'low severity' group appeared to respond better to mianserin. 4 There was a greater incidence of drug-related side-effects with doxepin treatment.
D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004316:Doxepin / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D003984:Dibenzazepines; D004316:Doxepin; D008803:Mianserin